Weight Loss Drugs & Temple Volume Loss: A Link?

The Food and Drug Administration has approved the use of the dermal filler Restylane® Contour™ for correcting temple hollowing, a cosmetic concern that’s seeing increased attention alongside the rise in popularity of weight-loss medications. This approval expands the uses for the hyaluronic acid-based filler, previously indicated for other facial aesthetic treatments.

Temple hollowing – the loss of volume in the temples – can create a sunken or gaunt appearance. While often associated with aging, the FDA notes that rapid weight loss, particularly when achieved through medication, can accelerate this volume loss. This suggests a growing demand for corrective procedures among individuals undergoing significant body composition changes. Medscape first reported on the approval.

Understanding Temple Hollowing and Volume Loss

As we age, the natural fat, muscle, and bone structure in our faces diminish, leading to a loss of volume. This is a gradual process, but it can be noticeably accelerated by rapid weight loss. Hyaluronic acid (HA) is a naturally occurring substance in the skin that helps retain moisture and provides volume. Dermal fillers containing HA, like Restylane® Contour™, are injected beneath the skin to restore lost volume and smooth out wrinkles and folds. The FDA’s approval specifically addresses the use of this particular filler to address the concavity that develops in the temple area.

The increasing prevalence of medications like GLP-1 receptor agonists (such as Ozempic and Wegovy) for weight management is believed to be a contributing factor to the heightened awareness of temple hollowing. These medications can lead to significant and relatively rapid weight loss, which can, in turn, make facial volume loss more apparent. WZID recently highlighted how the “weight loss boom is reshaping American aesthetics,” with a corresponding increase in demand for procedures to address related cosmetic concerns.

What the Approval Means for Patients

Prior to this approval, Restylane® Contour™ was primarily used for cheek augmentation and other mid-face applications. The expanded indication provides patients with a specifically approved option for addressing temple hollowing. It’s important to note that this approval doesn’t mean the procedure is without risk. As with any injectable treatment, potential side effects can include swelling, bruising, redness, and, rarely, more serious complications. Patients considering this treatment should discuss their medical history and expectations with a qualified and experienced healthcare professional.

Galderma’s Role and the Science Behind Restylane® Contour™

Galderma, the manufacturer of Restylane® Contour™, received FDA approval based on clinical trial data demonstrating the safety and efficacy of the filler for this indication. The filler utilizes Optimal Balance Technology™, designed to integrate naturally with the skin and provide a smooth, natural-looking result. Details regarding the specific trial design, sample size, and endpoints are available through Galderma’s official communications and potentially in peer-reviewed publications (though these were not readily available at the time of writing).

The Importance of Qualified Practitioners and Realistic Expectations

Dermal filler injections should only be performed by licensed and trained healthcare professionals – typically dermatologists, plastic surgeons, or registered nurses working under the supervision of a physician. Proper technique and a thorough understanding of facial anatomy are crucial to minimize the risk of complications and achieve optimal results. It’s also essential for patients to have realistic expectations. While dermal fillers can effectively restore volume and improve the appearance of temple hollowing, they are not a permanent solution. The effects typically last for several months to a year, depending on the individual and the specific product used. Maintenance treatments are usually required to sustain the results.

What Comes Next: Ongoing Surveillance and Potential for Expanded Applications

The FDA’s approval of Restylane® Contour™ for temple hollowing is likely to be followed by ongoing surveillance to monitor the long-term safety and effectiveness of the treatment. The FDA continuously reviews post-market data to identify any potential adverse events or unexpected outcomes. Galderma may continue to investigate the potential applications of Restylane® Contour™ for other facial aesthetic concerns. As the field of aesthetic medicine evolves, we can expect to notice further innovations in dermal filler technology and techniques, offering patients increasingly sophisticated options for addressing the signs of aging and volume loss.